M€ of AUM
Transactions
Employees
Operating since
GED Capital is an independent asset manager founded in 1996 that operates in the middle market. It currently manages more than €900 million through various asset classes such as private equity, venture capital and infrastructure. It has more than 50 domestic and foreign investors, including mainly pension funds, funds of funds, insurance companies, family offices and financial institutions.
Company
Independent
GED is an independent Private Equity group whose professional Partners hold a majority stake in the Management Companies of the Group.
International
Operating in the Iberian Peninsula, with offices in Madrid, Seville and Lisbon.
Commitment to Sustainability
As a signatory to the United Nations Principles for Responsible Investment (PRI), GED applies environmental, social and governance (ESG) criteria to its management model, ensuring permanent sustainable value creation for its managers and investments.
Stable team
An independent, stable and cohesive team of professionals whose experience amounts altogether to more than 200 years, through diverging economic cycles.
Deal flow owner
GED team and industrial network generates transactions in 3 different private equity sectors: Buyouts & growth, Infrastructure, Real Estate and Venture Capital. Proprietary transactions account for more than 2/3 of the total Deal Flow.
Activities
Private Equity
Real estate
Venture capital
Portfolio
Last news
GED acquires audiovisual company Cinelux from Nazca in a Secondary Buy-out transaction
GED Capital, a Private Equity firm operating in the lower/mid-market segment in Spain, has successfully closed the fifth investment from its Private Equity fund GED VI Spain, after acquiring…
GED Capital successfully exits healthcare company Vitro Group through a dual-track process
GED Capital (“GED”) divested Vitro Group (“Vitro” or the “Company”) through a dual exit route, first selling its flow cytometry division…
Vitro S.A. sells Cytognos to BD to prioritize the market launch of their new and disruptive Molecular Biology and Anatomic Pathology diagnostic platforms.
Seville, Spain (January 31, 2022) –Vitro S.A, (www.vitro.bio) a privately held company headquartered in Seville, Spain, announced today the sale of Cytognos to Becton Dickinson and Company (BD). Cytognos is a company specializing…
